Ildong Pharmaceutical Obtains US Patent for Type 2 Diabetes New Drug Substance... "Oral Medication Development Underway"

GLP-1RA Receptor Agonist

Ildong Pharmaceutical announced on the 11th that it has obtained a substance patent in the United States for the new drug candidate 'ID110521156' for the treatment of type 2 diabetes.

Exterior view of Ildong Pharmaceutical headquarters. [Photo by Ildong Pharmaceutical]

ID110521156 is a drug belonging to the glucagon-like peptide (GLP)-1 receptor agonist class, acting as an analog of the GLP-1 hormone that induces insulin secretion in the body to regulate blood glucose levels. The GLP-1 hormone is known to be produced by beta cells in the pancreas and is involved in insulin synthesis and secretion, reduction of blood glucose levels, regulation of gastrointestinal motility, and appetite suppression.

ID110521156 is a low molecular weight compound with the same function as the GLP-1 hormone. Compared to biologic drugs based on peptides, it is structurally stable and characterized by a long half-life in the bloodstream. Furthermore, Ildong Pharmaceutical explained that efficacy and safety evaluations using disease animal models confirmed significant effectiveness related to insulin secretion and blood glucose control, as well as superior safety compared to competitive drugs in the same class.

Ildong Pharmaceutical plans to develop this compound as an oral drug by leveraging its differentiated efficacy, safety, and stability derived from its structural characteristics. Oral drugs have advantages in terms of marketability, cost-effectiveness, and dosing convenience, distinguishing them from existing injectable drugs.

An Ildong Pharmaceutical official stated, "Regarding the development of ID110521156 as a treatment for type 2 diabetes, we are currently completing non-clinical studies and preparing to apply for clinical approval," adding, "We are also conducting production of clinical trial samples for this purpose."